Table 2 Comparison of clinical parameters between the non-HCQ and HCQ groups
COVID-19 patients (N = 154) | ||||
|---|---|---|---|---|
Demographics | Non-HCQ N = 59 (%) | HCQ N = 95 (%) | p value | |
Gender | ||||
Male | 36 (61.0) | 51 (53.7) | 0.372 | |
Female | 26 (39.0) | 44 (46.3) | ||
Age (years) | 61 (22–89) | 59 (21–90) | 0.254 | |
Systemic Arterial Hypertension | 30 (50.8) | 48 (50.5) | 0.969 | |
Type 2 diabetes mellitus | 19 (32.2) | 31 (32.6) | 0.956 | |
Obesity | 7 (11.9) | 17 (17.9) | 0.316 | |
COPD | 2 (3.4) | 4 (4.2) | 0.798 | |
Asthma | 0 | 5 (5.3) | 0.073 | |
Kidney disease | 6 (10.2) | 7 (7.4) | 0.543 | |
Hepatic disease | 0 | 3 (3.2) | 0.168 | |
Cardiopathy | 6 (10.2) | 7 (7.4) | 0.543 | |
Cancer | 20 (33.9) | 12 (12.6) | 0.002 | |
Autoimmune disease | 2 (3.4) | 4 (4.2) | 0.798 | |
Dyslipidemia | 4 (6.8) | 3 (3.2) | 0.294 | |
Neuro and psychiatric disorders | 7 (11.9) | 5 (5.3) | 0.137 | |
Smoking | ||||
Yes Ex | 3 (5.1) 7 (11.9) | 7 (7.4) 4 (4.2) | 0.183 | |
Alcoholic | ||||
Yes Ex | 1 (1.7) 4 (6.8) | 2 (2.1) 0 | 0.036 | |
Comorbidities | 55 (93.2) | 81 (85.3) | 0.135 | |
Comorbidities ≥ 2 | 43 (78.2) | 57 (70.4) | 0.311 | |
Pulmonary involvement > 50% | 20 (42.6) | 39 (55.7) | 0.163 | |
Pneumonia | 55 (93.2) | 94 (98.9) | 0.071 | |
ICU admission | 41 (69.5) | 76 (80.0) | 0.138 | |
Oseltamivir | 33 (55.9) | 85 (89.5) | < 0.001 | |
Azithromycin | 39 (66.1) | 91 (95.8) | < 0.001 | |
Corticosteroids | 40 (67.8) | 75 (78.9) | 0.122 | |
Heparin | 52 (88.1) | 94 (98.9) | 0.005 | |
Endotracheal Intubation | 12 (20.3) | 33 (34.7) | 0.056 | |
DVT | 1 (1.7) | 1 (1.1) | 1.000 | |